BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for X4 Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 5:51 pm Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 2,258,400 1.900% | -769,272 (-25.41%) | Filing |
| 2022-02-14 1:02 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 3,027,672 9.990% | 1,308,056 (+76.07%) | Filing |
| 2021-02-12 8:57 pm Purchase | 2020-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 1,719,616 9.990% | 59,141 (+3.56%) | Filing |
| 2020-02-14 5:06 pm Purchase | 2019-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 1,660,475 9.990% | 368,059 (+28.48%) | Filing |